Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Net Margin (2016 - 2025)

Historic Net Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 0.92%.

  • Akebia Therapeutics' Net Margin rose 544600.0% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.07%, marking a year-over-year decrease of 3190000.0%. This contributed to the annual value of 43.33% for FY2024, which is 4759200.0% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Net Margin of 0.92% as of Q3 2025, which was up 544600.0% from 0.4% recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Net Margin peaked at 23.3% during Q2 2022, and registered a low of 156.93% during Q2 2021.
  • Over the past 5 years, Akebia Therapeutics' median Net Margin value was 49.04% (recorded in 2024), while the average stood at 56.55%.
  • Data for Akebia Therapeutics' Net Margin shows a peak YoY increase of 2776000bps (in 2021) and a maximum YoY decrease of -646800bps (in 2021) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' Net Margin (Quarter) stood at 122.1% in 2021, then soared by 90bps to 11.66% in 2022, then skyrocketed by 96bps to 0.48% in 2023, then crashed by -10158bps to 49.04% in 2024, then surged by 102bps to 0.92% in 2025.
  • Its last three reported values are 0.92% in Q3 2025, 0.4% for Q2 2025, and 10.66% during Q1 2025.